Last reviewed · How we verify

DICL-SR — Competitive Intelligence Brief

DICL-SR (DICL-SR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID (nonsteroidal anti-inflammatory drug). Area: Rheumatology / Pain Management.

marketed NSAID (nonsteroidal anti-inflammatory drug) COX-1 and COX-2 Rheumatology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

DICL-SR (DICL-SR) — Kunming Baker Norton Pharmaceutical Sales Co., Ltd.. DICL-SR is a sustained-release formulation of diclofenac that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide anti-inflammatory, analgesic, and antipyretic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DICL-SR TARGET DICL-SR Kunming Baker Norton Pharmaceutical Sales Co., Ltd. marketed NSAID (nonsteroidal anti-inflammatory drug) COX-1 and COX-2
Cytotec Misoprostol Pfizer marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors 1988-01-01
Metamizole Sodium Metamizole Sodium Insel Gruppe AG, University Hospital Bern marketed Non-steroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
High Dose Ibuprofen High Dose Ibuprofen Ottawa Hospital Research Institute marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2
Loxoprofen sodium hydrogel patch Loxoprofen sodium hydrogel patch Sun Yat-sen University marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
ACULAR ACULAR University of South Alabama marketed NSAID (nonsteroidal anti-inflammatory drug) COX-1 and COX-2
Surgery with Naproxen Surgery with Naproxen Giovana Maria Weckwerth marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID (nonsteroidal anti-inflammatory drug) class)

  1. Depomed · 1 drug in this class
  2. Dong-A ST Co., Ltd. · 1 drug in this class
  3. Handok Inc. · 1 drug in this class
  4. Imprimis Pharmaceuticals, Inc. · 1 drug in this class
  5. Kunming Baker Norton Pharmaceutical Sales Co., Ltd. · 1 drug in this class
  6. LEO Pharma · 1 drug in this class
  7. Novartis · 1 drug in this class
  8. Pfizer · 1 drug in this class
  9. University of South Alabama · 1 drug in this class
  10. ZARS Pharma Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DICL-SR — Competitive Intelligence Brief. https://druglandscape.com/ci/dicl-sr. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing